RT Book, Section
A1 Taylor, Maida
A2 Silverman, Robert K.
SR Print(0)
ID 1139758822
T1 Metabolic Syndrome
T2 Obesity Medicine: Management of Obesity in Women's Health Care
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071843515
LK obgyn.mhmedical.com/content.aspx?aid=1139758822
RD 2024/04/19
AB In  1988,  at  the  Banting  Lecture  at  the  annual  meeting  of  the  American  Diabetes  Association,1  Dr.  Gerald  Reaven  of  Stanford  University  described  a  constellation  of  metabolic  abnormalities  associated  with  an  increased  risk  for  diabetes  and  atherosclerotic  cardiovascular  disease  (CVD).  This  cluster  of  risk  factors  was  designated  “syndrome  X,”  or  insulin  resistance  syndrome.  Dr.  Reaven  stated  that  persons  with  syndrome  X2  manifest  glucose  intolerance,  dyslipidemia,  abnormal  uric  acid  metabolism,  renal  salt  retention,  increased  sympathetic  tone,  and  hypercoagulability  due  to  increases  in  plasminogen  activator  inhibitor  1  (PAI-1).